{"prompt": "['MC1575', '38', 'Amendment 2', 'Any malignancy possibly related to cancer treatment (including AML/MDS)', 'should also be reported via the routine reporting mechanisms outlined in each', 'protocol.', '10.54 Second Malignancy', 'A second malignancy is one unrelated to the treatment of a prior malignancy (and is', 'NOT a metastasis from the initial malignancy). Second malignancies require ONLY', 'routine reporting unless otherwise specified', '10.55 Pregnancy, Fetal Death, and Death Neonatal', 'If a female subject (or female partner of a male subject) taking investigational', 'product becomes pregnant, the subject taking should notify the Investigator, and', 'the pregnant female should be advised to call her healthcare provider', 'immediately. The patient should have appropriate follow-up as deemed necessary', 'by her physician. If the baby is born with a birth defect or anomaly, a second', 'expedited report is required.', 'Prior to obtaining private information about a pregnant woman and her infant, the', 'investigator must obtain consent from the pregnant woman and the newborn', \"infant's parent or legal guardian before any data collection can occur. A consent\", 'form will need to be submitted to the IRB for these subjects if a pregnancy', 'occurs. If informed consent is not obtained, no information may be collected.', 'In cases of fetal death, miscarriage or abortion, the mother is the patient. In cases', 'where the child/fetus experiences a serious adverse event other than fetal death,', 'the child/fetus is the patient.', 'NOTE: When submitting Mayo Expedited Adverse Event Report reports for', '\"Pregnancy\", \"Pregnancy loss\", or \"Neonatal loss\", the potential risk of exposure', 'of the fetus to the investigational agent(s) or chemotherapy agent(s) should be', 'documented in the \"Description of Event\" section. Include any available medical', 'documentation. Include this form:', '10.551', 'Pregnancy', 'Pregnancy should be reported in an expedited manner as Grade 3', '\"Pregnancy, puerperium and perinatal conditions - Other', '(pregnancy)\" under the Pregnancy, puerperium and perinatal', 'conditions SOC. Pregnancy should be followed until the outcome is', 'known.', '10.552', 'Fetal Death', 'Fetal death is defined in CTCAE as \"A disorder characterized by death', 'in utero; failure of the product of conception to show evidence of', 'respiration, heartbeat, or definite movement of a voluntary muscle after', \"expulsion from the uterus, without possibility of resuscitation.'\", 'Any fetal death should be reported expeditiously, as Grade 4', '\"Pregnancy, puerperium and perinatal conditions - Other', '(pregnancy loss)\" under the Pregnancy, puerperium and perinatal', 'conditions SOC.', 'Protocol Version Date:16Aug2018']['MC1575', '39', 'Amendment 2', '10.553', 'Death Neonatal', 'Neonatal death, defined in CTCAE as \"A disorder characterized by', 'cessation of life occurring during the first 28 days of life\" that is felt by', 'the investigator to be at least possibly due to the investigational', 'agent/intervention, should be reported expeditiously.', 'A neonatal death should be reported expeditiously as Grade 4', '\"General disorders and administration - Other (neonatal loss)\"', 'under the General disorders and administration SOC.', '10.6', 'Required Routine Reporting', '10.61', 'Baseline and Adverse Events Evaluations', 'Pretreatment symptoms/conditions to be graded at baseline and adverse events to', 'be graded at each evaluation.', 'Grading is per CTCAE v4.0 unless alternate grading is indicated in the table', 'below:', 'Each', 'System Organ Class (SOC)', 'Adverse event/Symptoms', 'Baseline', 'evaluation', 'Blood and lymphatic system', 'Anemia', 'X', 'X', 'disorders', 'Gastrointestinal disorders', 'No. of stools', 'X', 'Diarrhea', 'X', 'Mucositis oral', 'X', 'Nausea', 'X', 'X', 'Oral dysesthesia', 'X', 'Vomiting', 'X', 'Weight loss', 'X', 'General disorders and', 'Fatigue', 'X', 'X', 'administration site conditions', 'Renal and urinary disorders', 'Proteinuria', 'X', 'X', 'Respiratory, thoracic and', 'Cough', 'X', 'X', 'mediastinal disorders', 'Skin and subcutaneous', 'Rash maculo-papular', 'X', 'X', 'disorders', 'Palmar-plantar', 'X', 'X', 'erythrodysesthesia syndrome', 'Vascular disorders', 'Hypertension', 'X', 'X', '10.62 Submit via appropriate MCCC Case Report Forms (i.e., paper or electronic, as', 'applicable) the following AEs experienced by a patient and not specified in', 'Section 10.6:', '10.621 Grade 2 AEs deemed possibly, probably, or definitely related to the study', 'treatment or procedure.', '10.622 Grade 3 and 4 AEs regardless of attribution to the study treatment or', 'procedure.', '10.623 Grade 5 AEs (Deaths)', '10.6231', \"Any death within 30 days of the patient's last study\", 'treatment or procedure regardless of attribution to the study', 'treatment or procedure.', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}